Does the “2+N Systematic Therapy” Make Type 2 Diabetes Remission Possible?

For many people, a diagnosis of type 2 diabetes mellitus (T2DM) means lifelong medication, strict glucose control, and constant risk of complications. In recent years, however, the concept of diabetes remission has quietly changed clinical practice: it is not a cure, but scientific intervention that maintains blood glucose at a non-diabetic level long-term without medication, significantly improving quality of life.
Recently, a landmark real-world study covering 1,000 patients with T2DM was published, focusing on an innovative “2+N Systematic Therapy”. The results showed that:

More than 1/3 of patients achieved diabetes remission
Nearly 70% had significant improvements in metabolic parameters

This clinical practice achievement developed in China brings new hope to hundreds of millions of people with diabetes. Today, we take an in-depth look at this study and unveil the mystery of the “2+N Systematic Therapy”.
Background
T2DM represents a major global public health challenge. Although traditional pharmacotherapy controls blood glucose, it rarely reverses insulin resistance and beta-cell dysfunction, often requiring lifelong drug use.
Recent studies (such as the DiRECT trial) have demonstrated that T2DM remission can be achieved by reducing liver and pancreatic fat through weight loss and lifestyle intervention early in the disease course. However, widespread implementation has been limited by low adherence and resource intensity.
To address this, the research team has implemented the “2+N Systematic Therapy” since 2015:

“2”: Integrated traditional Chinese and Western medicine pharmacology
“N”: Multidimensional lifestyle interventions including personalized nutrition, exercise, and psychological support

Preliminary practice showed significant effects on glucose control, weight loss, and metabolic improvement.
Study Design
This real-world study was conducted at the Diabetes and Obesity Reversal Center, Guangdong Second Provincial General Hospital from May 2015 to January 2022.A total of 1,000 adult overweight or obese (BMI ≥ 24 kg/m²) patients with T2DM were enrolled to evaluate the clinical efficacy of the “2+N Systematic Therapy”.
Inclusion criteria:

T2DM diagnosed per ADA/Chinese guidelines (HbA1c ≥ 6.5%, etc.)
Disease duration ≤ 5 years
Fasting C‑peptide ≥ 1.0 ng/mL
No severe complications

Exclusion criteria: secondary or autoimmune diabetes, end-stage organ damage.The selection criteria were consistent with the ABCD framework for diabetes remission evaluation.
The 2+N Systematic Therapy
The program was delivered by a multidisciplinary team:
“2” – Integrated Chinese and Western medication management

Short-term intensive insulin therapy followed by GLP‑1 RAs / metformin, with gradual tapering and discontinuation

“N” – Multidimensional lifestyle intervention

Personalized medical nutrition: 1000–1500 kcal/day, low-carbohydrate, high-protein
Structured exercise: ≥ 150 min/week of aerobic + resistance training
Psychological support and diabetes education

Approximately 80% of patients also received standardized acupuncture (e.g., ST36, CV6).A hybrid online + offline model was used, supported by an AI health app for diet, exercise, glucose tracking, and remote guidance.
Intervention period: 3–6 monthsAssessments: at baseline, 3 months, and 6 months
Primary endpoint: Clinical diabetes remission, defined as off all glucose-lowering drugs for ≥ 3 months and HbA1c < 6.5%.Secondary endpoints: body weight, HbA1c, blood lipids, HOMA-IR, and ectopic fat (measured by MRI in 26 patients).
Data were analyzed using R (v4.2.0) and GraphPad Prism 8, with P < 0.05 considered statistically significant.Although this was a non-randomized observational design, standardized intervention and strict follow-up strongly validated the feasibility, efficacy, and scalability of the 2+N Systematic Therapy for T2DM remission and metabolic remodeling in real-world settings.
Baseline Characteristics
Among 1,000 enrolled patients:

705 achieved clinical remission
295 did not achieve remission

The two groups were similar in age (remission 58.2±10.3 vs non‑remission 58.0±11.1 years, P=0.691).The non‑remission group had a higher proportion of women (63.1% vs 54.6%, P=0.014) and significantly higher body fat-related indices (weight, BMI, waist and hip circumference).
The non‑remission group also had higher HbA1c, fasting and postprandial glucose, insulin, and C‑peptide (except fasting C‑peptide), indicating more severe insulin resistance.Triglycerides were higher in the non‑remission group, while LDL‑C, HDL‑C, and beta-cell function (HOMA-β) were similar between groups.
Changes in Weight, BMI, and Body Circumference
During intervention, participants had significant reductions in body weight and central adiposity:

Mean weight: from 73.1±10.9 kg to 63.9±8.6 kg at 6 months
→ Net weight loss: 9.2±4.3 kg (P<0.05)
BMI: from 25.7±2.6 to 22.5±1.9 kg/m²
→ Reduction: 3.2±1.4 kg/m² (P<0.05)

Most weight loss occurred in the first 3 months (-5.3±2.6 kg, P<0.05), with continued gradual decline from 3 to 6 months.

Waist circumference: from 100.1±9.5 to 89.1±7.4 cm
→ Reduction: 11.0±4.2 cm (P<0.05)
Hip circumference: from 106.6±8.9 to 94.7±7.6 cm
→ Reduction: 12.0±4.2 cm (P<0.05)

All measures showed sustained, progressive improvement, reflecting effective control of central obesity.
Effects on Glycemic Control
After 2+N Systematic Therapy, glycemic control improved dramatically:

Mean HbA1c: from 7.3±1.3% to 5.4±0.5% at 3 months,stabilized at 5.3±0.4% at 6 months (non-diabetic range)→ Total reduction: -2.1±1.4% (P<0.001)
Fasting blood glucose (FBG): from 8.8±2.0 to 5.3±0.3 mmol/L→ Reduction: -3.5±2.0 mmol/L (P<0.05)
2-hour postprandial glucose: from 16.5±4.3 to 7.4±1.0 mmol/L→ Reduction: -9.1±4.3 mmol/L (P<0.05)

No significant further changes in FBG or postprandial glucose occurred between 3 and 6 months (P>0.05), indicating most patients reached near-normal glucose levels within 3 months and maintained stability.
At the 6-month endpoint, 705 out of 1,000 patients (70.5%) met the criteria for clinical diabetes remission.
Insulin Sensitivity and β‑Cell Function

HOMA-IR: from 5.4±2.6 to 3.1±1.2
→ Reduction: 2.4±2.4 (P<0.001), indicating markedly reduced insulin resistance

Beta-cell function (HOMA-β) was significantly enhanced at 6 months, demonstrating substantial recovery of insulin secretory capacity.
Effects on Metabolic Parameters
The therapy produced comprehensive metabolic benefits beyond glucose and weight control.At 6 months:

Triglycerides: from 6.04 to 1.39 mmol/L (mean reduction 4.9±3.1 mmol/L)
Total cholesterol: nearly halved (7.41 → 3.76 mmol/L, P<0.05)
LDL‑C: significantly decreased (3.42 → 1.89 mmol/L, P<0.05)
HDL‑C: slightly increased (≈1.0 → 1.2 mmol/L, not significant)

Serum uric acid: from 399 to 324 μmol/L (reduction -75 μmol/L, P<0.05), consistent with improved insulin resistance.No symptomatic gout occurred during rapid weight loss.
Key MRI findings (26 patients):Ectopic fat in the liver and pancreas decreased significantly as early as 1.5 months:

Liver fat: from 16.3% to 11.6% (P=0.017)
Whole pancreatic fat: from median 18.8% to 14.1% (P=0.002)
(head, body, and tail all decreased significantly)

Representative MRI showed reduced liver volume and increased pancreatic signal (lower fat density), consistent with quantitative data.These changes provide direct evidence for restored hepatic insulin sensitivity and improved beta-cell function, explaining the high remission rate.
Conclusions
The “2+N Systematic Therapy” provides a highly effective, non-surgical strategy for T2DM remission.By integrating Chinese and Western pharmacotherapy with personalized nutrition, exercise, psychology, and digital health support, the therapy achieved a 70.5% clinical remission rate in a real-world population.
This study not only validates the efficacy of the 2+N Systematic Therapy but also conveys a core message:The goal of T2DM management should go beyond “control” and pursue “remission” and even “metabolic remodeling”.